Mechanisms of epigenetic regulation of leukemia onset and progression.
暂无分享,去创建一个
Iannis Aifantis | Panagiotis Ntziachristos | J. Mullenders | P. Ntziachristos | T. Trimarchi | I. Aifantis | Jasper Mullenders | Thomas Trimarchi | Thomas Trimarchi
[1] A. Iwama,et al. Lethal myelofibrosis induced by Bmi1-deficient hematopoietic cells unveils a tumor suppressor function of the polycomb group genes , 2011, The Journal of experimental medicine.
[2] Kazuhiro Yoshida,et al. Promoter methylation of cyclin D2 gene in gastric carcinoma. , 2003, International journal of oncology.
[3] S. Gore. New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndrome. , 2011, Hematology. American Society of Hematology. Education Program.
[4] J. Stephenson,et al. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia , 1983, Nature.
[5] Peter W. Laird,et al. THE ROLE OF DNA METHYLATION IN CANCER GENETICS AND EPIGENETICS , 1996 .
[6] R. Copeland,et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas , 2010, Proceedings of the National Academy of Sciences.
[7] Madelaine Gogol,et al. Global Analysis of H3K4 Methylation Defines MLL Family Member Targets and Points to a Role for MLL1-Mediated H3K4 Methylation in the Regulation of Transcriptional Initiation by RNA Polymerase II , 2009, Molecular and Cellular Biology.
[8] Bin Tean Teh,et al. Somatic mutations of the histone H3K27 demethylase, UTX, in human cancer , 2009, Nature Genetics.
[9] M. Relling,et al. Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia , 2005, Cancer.
[10] Min Gyu Lee,et al. Demethylation of H3K27 Regulates Polycomb Recruitment and H2A Ubiquitination , 2007, Science.
[11] J. Hess,et al. CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis. , 2011, Cancer cell.
[12] O. Abdel-Wahab,et al. Disordered Epigenetic Regulation in the Pathophysiology of Myeloproliferative Neoplasms , 2012, Current Hematologic Malignancy Reports.
[13] S. Gygi,et al. The histone H 3 Lys 27 demethylase JMJD 3 regulates gene expression by impacting transcriptional elongation , 2012 .
[14] R. Paro,et al. Interpretation of developmental signaling at chromatin: the Polycomb perspective. , 2010, Developmental cell.
[15] A. Belkina,et al. BET domain co-regulators in obesity, inflammation and cancer , 2012, Nature Reviews Cancer.
[16] Iannis Aifantis,et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. , 2012, Cancer cell.
[17] J. Soulier,et al. Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.
[18] S. Robson,et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.
[19] J. Melo,et al. The molecular biology of chronic myeloid leukemia. , 2000, Blood.
[20] A. Pession,et al. The Role of HDACs Inhibitors in Childhood and Adolescence Acute Leukemias , 2011, Journal of biomedicine & biotechnology.
[21] Timothy J. Durham,et al. Systematic analysis of chromatin state dynamics in nine human cell types , 2011, Nature.
[22] A. Ferrando,et al. Genetic Inactivation of the PRC2 Complex in T-Cell Acute Lymphoblastic Leukemia , 2011, Nature Medicine.
[23] Kristian Helin,et al. Polycomb group proteins: navigators of lineage pathways led astray in cancer , 2009, Nature Reviews Cancer.
[24] Dinshaw J. Patel,et al. Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger , 2009, Nature.
[25] Tony Kouzarides,et al. Targeting epigenetic readers in cancer. , 2012, The New England journal of medicine.
[26] M. Hallek,et al. Hematological cancer in 2011: New therapeutic targets and treatment strategies , 2012, Nature Reviews Clinical Oncology.
[27] David R. Liu,et al. Conversion of 5-Methylcytosine to 5- Hydroxymethylcytosine in Mammalian DNA by the MLL Partner TET1 , 2009 .
[28] Howard Y. Chang,et al. A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression , 2011, Nature.
[29] Zev A. Binder,et al. The Genetic Landscape of the Childhood Cancer Medulloblastoma , 2011, Science.
[30] Li Ding,et al. Recurrent DNMT3A Mutations in Patients with Myelodysplastic Syndromes , 2011, Leukemia.
[31] S. Mathew,et al. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23) , 2003, Leukemia.
[32] S. Lowe,et al. The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;NrasG12D acute myeloid leukemia , 2013, Oncogene.
[33] Jin He,et al. KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia. , 2011, Blood.
[34] Michael S. Becker,et al. Spatial Organization of the Mouse Genome and Its Role in Recurrent Chromosomal Translocations , 2012, Cell.
[35] I. Amit,et al. Comprehensive mapping of long range interactions reveals folding principles of the human genome , 2011 .
[36] A. Chess,et al. Gene Body-Specific Methylation on the Active X Chromosome , 2007, Science.
[37] W. Kaelin,et al. Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases. , 2011, Cold Spring Harbor symposia on quantitative biology.
[38] Maite Huarte,et al. The X-Linked Mental Retardation Gene SMCX/JARID1C Defines a Family of Histone H3 Lysine 4 Demethylases , 2007, Cell.
[39] A. Feinberg. An Epigenetic Approach to Cancer Etiology , 2007, Cancer journal.
[40] K. Wagner,et al. Rare occurrence of DNMT3A mutations in myelodysplastic syndromes , 2011, Haematologica.
[41] A. F. Stewart,et al. Increased apoptosis and skewed differentiation in mouse embryonic stem cells lacking the histone methyltransferase Mll2. , 2007, Molecular biology of the cell.
[42] P. Opolon,et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. , 2011, Cancer cell.
[43] B. Druker,et al. Translation of the Philadelphia chromosome into therapy for CML. , 2008, Blood.
[44] L. Di Croce,et al. Dynamics of epigenetic modifications in leukemia. , 2011, Briefings in functional genomics.
[45] Michel C. Nussenzweig,et al. Translocation-Capture Sequencing Reveals the Extent and Nature of Chromosomal Rearrangements in B Lymphocytes , 2011, Cell.
[46] Christopher J. Schofield,et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response , 2012, Nature.
[47] Martin Dugas,et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia , 2012, Nature Medicine.
[48] S. Balasubramanian,et al. Quantitative Sequencing of 5-Methylcytosine and 5-Hydroxymethylcytosine at Single-Base Resolution , 2012, Science.
[49] M. Caligiuri,et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] R. Young,et al. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.
[51] M. Esteller. Epigenetics in cancer. , 2008, The New England journal of medicine.
[52] N. Casadevall,et al. Common 4q24 deletion in four cases of hematopoietic malignancy: early stem cell involvement? , 2005, Leukemia.
[53] Hideo Ema,et al. De novo DNA methyltransferase is essential for self-renewal, but not for differentiation, in hematopoietic stem cells , 2007, The Journal of experimental medicine.
[54] Min Gyu Lee,et al. p53 is regulated by the lysine demethylase LSD1 , 2007, Nature.
[55] X. Yang,et al. MOZ and MORF, two large MYSTic HATs in normal and cancer stem cells , 2007, Oncogene.
[56] Thomas A Milne,et al. Regulation of MLL1 H3K4 methyltransferase activity by its core components , 2006, Nature Structural &Molecular Biology.
[57] Tom Misteli,et al. Spatial proximity of translocation-prone gene loci in human lymphomas , 2003, Nature Genetics.
[58] Yong-mei Zhu,et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia , 2011, Nature Genetics.
[59] G. Ming,et al. Hydroxylation of 5-Methylcytosine by TET1 Promotes Active DNA Demethylation in the Adult Brain , 2011, Cell.
[60] Lars Bullinger,et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. , 2011, Cancer cell.
[61] D. Gilliland,et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. , 2009, Blood.
[62] Manolis Kellis,et al. Discovery and characterization of chromatin states for systematic annotation of the human genome , 2010, Nature Biotechnology.
[63] G. Huls,et al. Gene expression profiling in acute myeloid leukaemia. , 2011, The Netherlands journal of medicine.
[64] Johan Auwerx,et al. Histone methyl transferases and demethylases; can they link metabolism and transcription? , 2010, Cell metabolism.
[65] T. Kundu,et al. Polyisoprenylated Benzophenone, Garcinol, a Natural Histone Acetyltransferase Inhibitor, Represses Chromatin Transcription and Alters Global Gene Expression* , 2004, Journal of Biological Chemistry.
[66] R. Young,et al. A Chromatin Landmark and Transcription Initiation at Most Promoters in Human Cells , 2007, Cell.
[67] Ty C. Voss,et al. DNA damage defines sites of recurrent chromosomal translocations in B lymphocytes , 2012, Nature.
[68] A. Weinmann,et al. Jmjd3 and UTX play a demethylase-independent role in chromatin remodeling to regulate T-box family member-dependent gene expression. , 2010, Molecular cell.
[69] S. Armstrong,et al. Targeting epigenetic programs in MLL-rearranged leukemias. , 2011, Hematology. American Society of Hematology. Education Program.
[70] Kenneth H. Buetow,et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia , 2011, Nature.
[71] N. Socci,et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.
[72] Stefano Monti,et al. Genome-wide Translocation Sequencing Reveals Mechanisms of Chromosome Breaks and Rearrangements in B Cells , 2011, Cell.
[73] D. Birnbaum,et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms , 2010, Leukemia.
[74] S. Forman,et al. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli , 2005, Leukemia.
[75] Christian Bastard,et al. TET2 and DNMT3A mutations in human T-cell lymphoma. , 2012, The New England journal of medicine.
[76] Role for Dpy-30 in ES Cell-Fate Specification by Regulation of H3K4 Methylation within Bivalent Domains , 2011, Cell.
[77] G. Boucher,et al. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. , 2012, Genes & development.
[78] Paul Tempst,et al. JHDM2A, a JmjC-Containing H3K9 Demethylase, Facilitates Transcription Activation by Androgen Receptor , 2006, Cell.
[79] R. Jaenisch,et al. Induction of Tumors in Mice by Genomic Hypomethylation , 2003, Science.
[80] K. Bible,et al. Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress. , 2007, Blood.
[81] Joshua F. McMichael,et al. DNMT3A mutations in acute myeloid leukemia. , 2010, The New England journal of medicine.
[82] M. Herlyn,et al. Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase. , 2010, Cancer cell.
[83] O. Abdel-Wahab,et al. TET family proteins and their role in stem cell differentiation and transformation. , 2011, Cell stem cell.
[84] H. Drexler,et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders , 2010, Nature Genetics.
[85] A. Shilatifard,et al. The super elongation complex (SEC) and MLL in development and disease. , 2011, Genes & development.
[86] O. Abdel-Wahab,et al. The role of mutations in epigenetic regulators in myeloid malignancies , 2012, Nature Reviews Cancer.
[87] Feng-Chun Yang,et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. , 2011, Blood.
[88] M. Tanimoto,et al. A novel fusion variant of the MORF and CBP genes detected in therapy‐related myelodysplastic syndrome with t(10;16)(q22;p13) , 2003, British journal of haematology.
[89] T. Mikkelsen,et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells , 2008, Nature.
[90] C. Pui,et al. Treatment of acute lymphoblastic leukemia. , 2006, The New England journal of medicine.
[91] Yong Jiang,et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27) , 2012, Proceedings of the National Academy of Sciences.
[92] Crispin J. Miller,et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. , 2012, Cancer cell.
[93] Chao Lu,et al. Metabolic regulation of epigenetics. , 2012, Cell Metabolism.
[94] C. Croce,et al. Knockdown of ALR (MLL2) Reveals ALR Target Genes and Leads to Alterations in Cell Adhesion and Growth , 2006, Molecular and Cellular Biology.
[95] Michael B. Stadler,et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome , 2007, Nature Genetics.
[96] J. Licht,et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.
[97] C. Allis,et al. Translating the Histone Code , 2001, Science.
[98] Zhike Lu,et al. Identification of 67 Histone Marks and Histone Lysine Crotonylation as a New Type of Histone Modification , 2011, Cell.
[99] D. Gilliland,et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis , 2009, Leukemia.
[100] A. Deblasio,et al. JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. , 2011, Cancer cell.
[101] P. Laird,et al. Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina–associated domains , 2011, Nature Genetics.
[102] Kristian Helin,et al. Molecular mechanisms and potential functions of histone demethylases , 2012, Nature Reviews Molecular Cell Biology.
[103] S. Armstrong,et al. Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia , 2012, Leukemia.
[104] E. Raetz,et al. Molecular pathogenesis of T-cell leukaemia and lymphoma , 2008, Nature Reviews Immunology.
[105] Ali Shilatifard,et al. Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis , 2010, Nature Reviews Cancer.
[106] Francisco Cervantes,et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.
[107] Timothy J. Durham,et al. Combinatorial Patterning of Chromatin Regulators Uncovered by Genome-wide Location Analysis in Human Cells , 2011, Cell.
[108] H. Alder,et al. The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene , 1992, Cell.
[109] Peter A. Jones,et al. The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.
[110] R. Jaenisch,et al. Global loss of imprinting leads to widespread tumorigenesis in adult mice. , 2005, Cancer cell.
[111] Robert E. Kingston,et al. Mechanisms of Polycomb gene silencing: knowns and unknowns , 2009, Nature Reviews Molecular Cell Biology.
[112] N. Bertos,et al. Identification of a Human Histone Acetyltransferase Related to Monocytic Leukemia Zinc Finger Protein* , 1999, The Journal of Biological Chemistry.
[113] S. Raimondi,et al. Leukemic mutations in the methylation‐associated genes DNMT3A and IDH2 are rare events in pediatric AML: A report from the Children's Oncology Group , 2011, Pediatric blood & cancer.
[114] C. Allis,et al. Covalent histone modifications — miswritten, misinterpreted and mis-erased in human cancers , 2010, Nature Reviews Cancer.
[115] Israel Steinfeld,et al. Developmental programming of CpG island methylation profiles in the human genome , 2009, Nature Structural &Molecular Biology.
[116] J. Herman,et al. The Epigenetic promise for prostate cancer diagnosis , 2012, The Prostate.
[117] C. Roberts,et al. SWI/SNF nucleosome remodellers and cancer , 2011, Nature Reviews Cancer.
[118] C. Allis,et al. Histone arginine methylation and its dynamic regulation. , 2006, Frontiers in bioscience : a journal and virtual library.
[119] S. Armstrong,et al. Polycomb repressive complex 2 is required for MLL-AF9 leukemia , 2012, Proceedings of the National Academy of Sciences.
[120] A. Green,et al. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. , 2010, The New England journal of medicine.
[121] E. Giné,et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia , 2011, Nature Genetics.
[122] Qi Xie,et al. Methylation-mediated regulation of E2F1 in DNA damage-induced cell death , 2011, Journal of receptor and signal transduction research.
[123] C. Disteche,et al. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB–binding protein , 1996, Nature Genetics.
[124] S. Korsmeyer,et al. Definitive hematopoiesis requires the mixed-lineage leukemia gene. , 2004, Developmental cell.
[125] O. Abdel-Wahab,et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. , 2011, Cancer cell.
[126] P. Veys,et al. Long‐term follow‐up of relapsed childhood acute lymphoblastic leukaemia , 2003, British journal of haematology.
[127] Axel Imhof,et al. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9 , 2005, Nature chemical biology.
[128] M. Dawson,et al. Cancer Epigenetics: From Mechanism to Therapy , 2012, Cell.
[129] Guillaume J. Filion,et al. Systematic Protein Location Mapping Reveals Five Principal Chromatin Types in Drosophila Cells , 2010, Cell.
[130] Danny Reinberg,et al. Molecular Signals of Epigenetic States , 2010, Science.
[131] Ryan D. Morin,et al. Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin , 2010, Nature Genetics.
[132] R. Jaenisch,et al. Chromosomal Instability and Tumors Promoted by DNA Hypomethylation , 2003, Science.
[133] Veronika Rockova,et al. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. , 2012, Blood.
[134] A. Viale,et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012, Nature.
[135] M. Fraga,et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer , 2005, Nature Genetics.
[136] B. Ponder,et al. Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers , 2011, International journal of cancer.
[137] S. Henikoff,et al. Genome-wide analysis of Arabidopsis thaliana DNA methylation uncovers an interdependence between methylation and transcription , 2007, Nature Genetics.
[138] H. Goldschmidt,et al. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma , 2012, Leukemia & lymphoma.
[139] D. Reinberg,et al. The Polycomb complex PRC2 and its mark in life , 2011, Nature.
[140] Omar Abdel-Wahab,et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. , 2010, Cancer cell.
[141] Raul Rabadan,et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma , 2010, Nature.
[142] Benjamin J. Raphael,et al. The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .
[143] S. Berger,et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation , 2012, Nature.
[144] Dustin E. Schones,et al. Genome-wide Mapping of HATs and HDACs Reveals Distinct Functions in Active and Inactive Genes , 2009, Cell.
[145] Mark Ptashne,et al. On the use of the word ‘epigenetic’ , 2007, Current Biology.
[146] Howard Y. Chang,et al. Long Noncoding RNA as Modular Scaffold of Histone Modification Complexes , 2010, Science.
[147] A. Tarakhovsky,et al. Polycomb protein Ezh2 regulates pancreatic beta-cell Ink4a/Arf expression and regeneration in diabetes mellitus. , 2009, Genes & development.
[148] M. Fraga,et al. The Polycomb group protein EZH2 directly controls DNA methylation , 2006, Nature.
[149] Raymond K. Auerbach,et al. Extensive Promoter-Centered Chromatin Interactions Provide a Topological Basis for Transcription Regulation , 2012, Cell.
[150] Huidong Shi,et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. , 2009, Blood.
[151] J. Cortes,et al. Molecular targeted therapy in acute myeloid leukemia , 2012, Hematology.
[152] Kiran C. Bobba,et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia , 2012, Nature.
[153] Ryan D. Morin,et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. , 2011, Blood.
[154] J. Herman,et al. Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.
[155] E. Li,et al. The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation , 2009, Nature Genetics.
[156] Xiaofeng Jiang,et al. Inhibition of histone acetyltransferase activity by anacardic acid sensitizes tumor cells to ionizing radiation , 2006, FEBS letters.
[157] B. Bernstein,et al. Charting histone modifications and the functional organization of mammalian genomes , 2011, Nature Reviews Genetics.
[158] M. Esteller. Cancer epigenomics: DNA methylomes and histone-modification maps , 2007, Nature Reviews Genetics.
[159] R. DePinho,et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. , 2006, Cancer research.
[160] Kazuhiko Aoyagi,et al. Discovery of aberrant expression of R-RAS by cancer-linked DNA hypomethylation in gastric cancer using microarrays. , 2005, Cancer research.
[161] William B. Smith,et al. Selective inhibition of BET bromodomains , 2010, Nature.
[162] Howard Y. Chang,et al. Long noncoding RNA HOTAIR reprograms chromatin state to promote cancer metastasis , 2010, Nature.
[163] G. Hon,et al. Base-Resolution Analysis of 5-Hydroxymethylcytosine in the Mammalian Genome , 2012, Cell.
[164] Michael L. Cleary,et al. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias , 1992, Cell.
[165] Guy Sauvageau,et al. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. , 2010, Cell stem cell.
[166] Fazli Wahid,et al. Curcumin in Cancer Chemoprevention: Molecular Targets, Pharmacokinetics, Bioavailability, and Clinical Trials , 2010, Archiv der Pharmazie.
[167] C. Bloomfield,et al. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia , 2012, Leukemia.
[168] A. Younes,et al. Histone deacetylase inhibitors in lymphoma , 2010, Current opinion in oncology.
[169] R. McLendon,et al. IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.
[170] D. Reinberg,et al. Chromatin structure and the inheritance of epigenetic information , 2010, Nature Reviews Genetics.
[171] J. Berg,et al. Dnmt3a is essential for hematopoietic stem cell differentiation , 2011, Nature Genetics.
[172] Irving L. Weissman,et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells , 2003, Nature.
[173] L. Aravind,et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2 , 2010, Nature.
[174] Yonghong Xiao,et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. , 2011, Cancer cell.
[175] C. Bloomfield,et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.
[176] James A. Cuff,et al. A Bivalent Chromatin Structure Marks Key Developmental Genes in Embryonic Stem Cells , 2006, Cell.
[177] G. Hon,et al. Predictive chromatin signatures in the mammalian genome. , 2009, Human molecular genetics.
[178] O. Abdel-Wahab,et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. , 2010, Cancer research.
[179] O. Elemento,et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. , 2010, Blood.
[180] H. Erdjument-Bromage,et al. Histone demethylation by a family of JmjC domain-containing proteins , 2006, Nature.